Regulation of volume-regulated anion channels alters sensitivity to platinum chemotherapy

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Cisplatin is a cornerstone chemotherapy for many cancers, but treatment failure due to drug resistance significantly limits patient survival.
• Puromycin-sensitive aminopeptidase (NPEPPS) has been identified as a potential therapeutic target that drives cisplatin resistance.
• The precise molecular mechanisms underlying NPEPPS-mediated cisplatin resistance remain incompletely understood.

Purpose of the Study:

• To elucidate the general mechanism by which NPEPPS contributes to cisplatin resistance across various cancer types.
• To investigate the interaction between NPEPPS and volume-regulated anion channels (VRACs) in regulating cisplatin cellular uptake.
• To evaluate the NPEPPS/VRAC gene expression ratio as a predictive biomarker for cisplatin response.

Main Methods:

• In vitro and in vivo experiments using cancer models.
• Analysis of patient-derived organoids.
• Gene expression analysis in multiple human cancer cohorts.
• Investigation of the interaction between NPEPPS and VRACs.

Main Results:

• NPEPPS interacts with VRACs to control the intracellular import of cisplatin, thereby modulating cellular response to the drug.
• The ratio of NPEPPS to VRAC gene expression serves as a predictive indicator of cisplatin efficacy in diverse cancer patient groups.
• This mechanism of cisplatin resistance is broadly applicable across multiple cancer types.

Conclusions:

• The interaction between NPEPPS and VRACs represents a key mechanism driving cisplatin resistance in cancer.
• Targeting NPEPPS offers a promising therapeutic strategy to overcome cisplatin resistance and improve patient outcomes.
• The NPEPPS/VRAC ratio is a valuable predictive biomarker for guiding cisplatin-based chemotherapy decisions.
• The findings also shed light on VRAC regulation in normal cellular volume homeostasis, with implications beyond cancer therapy.